



**We are looking for people to join our study who have early-stage breast cancer or ovarian cancer in remission, and who are afraid of their cancer.**

**Why is this study being done?**

The purpose of this study is to look at how psilocybin-assisted psychotherapy affects the fear of cancer recurrence in patients with early-stage breast cancer or ovarian cancer in remission.

**What is psilocybin-assisted psychotherapy?**

In this study, each person in the study will be given a single, oral “high” (25 mg) dose of psilocybin. They will also have psychotherapy sessions with a therapist.

**What happens during this study?**

People who join this study will have 11 study visits during a 6-month time period. About 2 to 4 of the study visits are in person (this number will be decided by the research leader). The rest of the visits are remote (not in-person).

**To take part in this study, you must:**

- Go to in-person visits for screening, baseline and to take the medicine (called the dosing session), and also a final follow-up visit.
- Have virtual study visits, which will include preparatory and integration sessions with the study therapists. You will also be asked to do certain tasks at your research study visits.
- Have a support person who can stay with you after the dosing session.
- It must be 6 months from the end of your treatment plan (end of surgery, radiation or chemotherapy).

**What you will receive:**

- You will not be paid (compensated) for being part of the study. However, the psilocybin and psychotherapy sessions are free.

**Principal investigator:** Stacy Fischer, MD

**For more information, please contact the project manager:** Mary Mancuso

[mary.mancuso@cuanschutz.edu](mailto:mary.mancuso@cuanschutz.edu)

Phone: 303.724.5729